GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference: Fireside Chat Date: Tuesday, March 4, 2025 Time: 9:10 – 9:40 a.m. Eastern Time (ET) Location: Boston, MA   Conference Event: Investor Meetings Date: Tuesday, March 4, 2025 Leerink Partners 2025 Global Healthcare Conference: Presentation ...

Novavax (NVAX) incurred a fourth-quarter 2024 loss of 51 cents per share, narrower than the Zacks Consensus Estimate of a loss of 75 cents. In the year-ago quarter, the company reported a loss of $1.44 per share.Revenues in the quarter amounted to $88.3 million, which beat the Zacks Consensus Estimate of $86 million. However, the top line declined 70% on a year-over-year basis.See the Zacks Earnings Calendar to stay ahead of market-making news.Year to date, Novavax stock has declined 9% against the industry ...

Novavax, Inc. (NASDAQ:NVAX) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development John Trizzino - President and Chief Operating Officer Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Robert Walker - Senior Vice President and Chief Medical Officer Conference Call Particip ...

On Thursday, Novavax Inc NVAX reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the consensus of $84.35 million. The decrease was due to lower product sales under APA agreements.The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from $1.44 a year ago, in line with the Wall Street Estimate.Also Read: Wegovy Maker Novo Nordisk To Buy Novavax’s Czech Republic Manufacturing Facility For $200 Million“In 2024, we unveiled our new corporate ...

Novavax (NVAX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.44 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this vaccine maker would post a loss of $0.87 per share when it actually produced a loss of $0.76, delivering a surprise of 12.64%.Over the last four quarters, the company has surpassed con ...

Fourth Quarter 2024 Financial Results and Operational Highlights February 27, 2025 © 2025 NOVAVAX. All rights reserved. NovavaxTM (and all associated logos) is a trademark of Novavax, Inc. Matrix-MTM is a trademark of Novavax AB. 2 © 2025 NOVAVAX. All rights reserved. Non-GAAP Financial Measures The Company has used a non-GAAP financial measure in this presentation, which is Adjusted Licensing, Royalties and Other Revenue. Non-GAAP financial measures refer to financial information adjusted from financial me ...

COVID-19 Vaccine Developments - Novavax achieved approximately 70% market share in a regional retailer for its COVID-19 vaccine during the 2024-2025 season[26] - The company reported a $50 million milestone from Sanofi related to a COVID-19 pediatric trial[21] - Novavax's COVID-19 vaccine induces broad neutralizing responses across all tested variants, indicating acceptable coverage against currently circulating variants[26] - The partnership with Sanofi includes a co-exclusive license to co-commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide[24] - Novavax's COVID-19 vaccine was launched in multiple markets, with a focus on driving value through R&D and diversified partnerships[16] - Novavax's late-stage pipeline includes a Phase 3 trial for a combination influenza and COVID-19 vaccine initiated in December 2024, with an initial cohort of approximately 2,000 participants[32][36] - The U.S. COVID-19 BLA PDUF is expected to be a significant focus in the near future[75] Financial Performance and Projections - Novavax's preliminary financial data for the year ended December 31, 2024, is still being finalized and may differ materially from actual results[7] - Novavax anticipates combined R&D and SG&A expenses of $700 million to $750 million for FY 2024, with a portion expected to be reimbursed by Sanofi[66] - Full year 2024 product sales guidance includes approximately $100 million in APA dose deliveries in 1H 2024 and $125 million in commercial market sales in 2H 2024[70] - Full year 2024 licensing, royalties, and other revenue guidance includes $450 million from the Sanofi agreement upfront payment and $25 million in royalty and other revenue from partner-related activities[70] - Current liabilities have decreased by over $1.3 billion since the end of 2022, including a settlement with Gavi[71] - The sale of the CZ manufacturing facility to Novo Nordisk generated $200 million in non-dilutive capital and annual cost reductions of approximately $80 million[71] Partnerships and Collaborations - The Sanofi partnership is expected to create multiple revenue streams and enhance access to Novavax's technology[24] - Sanofi partnership includes a $500 million upfront payment received in Q2 2024, with additional milestone payments totaling $700 million expected through 2026[28] - The company expects to receive ~$450 million in reimbursements from Sanofi for FY 2025, net of expected expenses[68] - The company is pursuing partnerships for its differentiated combination influenza vaccine candidates targeting older adults[37] - The company reported a significant interest in partnering or out-licensing its Matrix-M adjuvant technology[30] Research and Development - The company is focused on a lean operating model to drive shareholder value and has a diversified vaccine pipeline including COVID-19 and influenza candidates[12] - Novavax's technology platform is based on a recombinant protein-based nanoparticle, which is clinically proven and adaptable for combination vaccines[14] - Novavax's Matrix-M™ adjuvant shows promise in enhancing immune responses and is being explored for use in new vaccine formulations[46][47] - Novavax's H5N1 avian pandemic influenza vaccine candidate is currently undergoing preclinical evaluation, with the ability to pivot to new strains as they emerge[42] - The company anticipates advancements in its early-stage pipeline and enhanced partnerships in the coming years[75] Milestones and Future Outlook - Key milestones for 2025 include additional Sanofi-related milestones and data from late-stage assets[75] - Data from the initial cohort in the influenza Phase 3 trial is anticipated in 2025[76]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-26770 NOVAVAX, INC. (Exact name of Registrant as specified in its charter) Delaware 22-2816046 (State of incorporation) (I.R.S. ...

Company Performance - Novavax (NVAX) closed at $7.92, reflecting a -1.25% change from the previous day's closing price, underperforming the S&P 500's daily loss of 0.43% [1] - The stock has decreased by 9.17% over the past month, contrasting with the Medical sector's gain of 4.6% and the S&P 500's gain of 2.6% [1] Earnings Expectations - The upcoming earnings report for Novavax is expected to show an EPS of -$0.67, which represents a 53.47% increase compared to the same quarter last year [2] - Revenue is projected to be $90.72 million, indicating a significant decline of 68.86% from the equivalent quarter last year [2] Analyst Estimates - Recent changes in analyst estimates for Novavax reflect shifting short-term business dynamics, with positive revisions indicating optimism about the company's profitability [3] - The Zacks Rank system, which incorporates these estimate changes, provides actionable ratings for investors [4] Zacks Rank and Performance - Novavax currently holds a Zacks Rank of 2 (Buy), with the consensus EPS estimate having increased by 2899.99% over the past month [5] - Historically, stocks rated 1 (Strong Buy) have delivered an average annual return of +25% since 1988 [5] Valuation Metrics - Novavax has a Forward P/E ratio of 100.25, which is significantly higher than the industry's average Forward P/E of 23.12 [6] - The company has a PEG ratio of 2.88, compared to the average PEG ratio of 1.67 for Medical - Biomedical and Genetics stocks [7] Industry Context - The Medical - Biomedical and Genetics industry is part of the Medical sector and currently holds a Zacks Industry Rank of 67, placing it in the top 27% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Points - Novavax, Inc. will report its fourth quarter and full year 2024 financial results and operational highlights on February 27, 2025, at 8:30 a.m. ET [1] - The company specializes in protein-based vaccines and utilizes its proprietary Matrix-M™ adjuvant to enhance immune response [3] Conference Call Details - The conference call is scheduled for February 27, 2025, at 8:30 a.m. U.S. ET, with a registration URL provided for participants [1] - A replay of the call will be available starting at 11:30 a.m. U.S. ET on the same day until March 6, 2025 [2] Company Overview - Novavax is based in Gaithersburg, Maryland, and focuses on developing innovative vaccines for serious infectious diseases [3] - The company's portfolio includes a COVID-19 vaccine and candidates for COVID-19-Influenza Combination and stand-alone influenza vaccines [3] - Novavax's adjuvant is also part of the malaria vaccine developed by the University of Oxford and Serum Institute of India [3]